on GENFIT (EPA:GNFT)
GENFIT Reports on Half-Year Liquidity Contract with Crédit Industriel et Commercial
GENFIT, a biopharmaceutical company listed on Nasdaq and Euronext, released its half-year report for the liquidity contract with Crédit Industriel et Commercial. As of June 30, 2025, GENFIT's liquidity account held 201,100 shares and €398,484.67.
Throughout the first half of 2025, GENFIT executed 2,673 buy trades for 1,412,901 shares worth €5,016,550.43, and 1,894 sell trades for 1,419,301 shares, totaling €5,061,074.96. At the start of the contract, resources included 27,911 shares and €769,849.43.
GENFIT, with a focus on liver diseases, operates in Lille, Cambridge, and Zurich. This report reflects their financial positioning amidst their R&D commitments in treating rare liver conditions.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news